Abstract
A pilot study was conducted employing a well known mouse model for Alzheimers disease to evaluate the anti-amyloid efficacy of three FDA pre-approved drugs. Paroxetine (SSRI and APP 5UTR directed lead compound), Nacetyl cysteine (antioxidant), and erythromycin (macrolide antibiotic) were provided to the drinking water of TgCRND8 mice for three months. This report provides data that measured the steady-state levels of amyloid Aβ-40 and Aβ-42 Aβ as pmol Aβ per gram of mouse brain cortex in drug treated and placebo animals. The relative levels of Ab peptide levels were reduced after exposure of mice to paroxetine (N=5), NAC (N=7), and erythromycin (N=7) relative to matched placebo counterparts. These results demonstrated proof-of concept for a strategy to further screen the APP 5UTR target to identify novel drugs that exhibit anti-amyloid efficacy in vivo. These data also demonstrated a statistically significant antiamyloid trend for paroxetine, NAC and erythromycin. The potential for conducting further studies with these compounds using larger cohorts of TgCRND8 mice is discussed.
Keywords: amyloid precursor protein(app), desferrioxamine, phenserine, dimercaptopropanol, antioxidant, transgenic mice, (nsaid), nucleotide
Current Alzheimer Research
Title: Pilot Study of the Reducing Effect on Amyloidosis In Vivo by Three FDA Pre-Approved Drugs Via the Alzheimers APP 5Untranslated Region
Volume: 2 Issue: 2
Author(s): Stephanie Tucker, Michelle Ahl, Ashley Bush, David Westaway, Xudong Huang and Jack T. Rogers
Affiliation:
Keywords: amyloid precursor protein(app), desferrioxamine, phenserine, dimercaptopropanol, antioxidant, transgenic mice, (nsaid), nucleotide
Abstract: A pilot study was conducted employing a well known mouse model for Alzheimers disease to evaluate the anti-amyloid efficacy of three FDA pre-approved drugs. Paroxetine (SSRI and APP 5UTR directed lead compound), Nacetyl cysteine (antioxidant), and erythromycin (macrolide antibiotic) were provided to the drinking water of TgCRND8 mice for three months. This report provides data that measured the steady-state levels of amyloid Aβ-40 and Aβ-42 Aβ as pmol Aβ per gram of mouse brain cortex in drug treated and placebo animals. The relative levels of Ab peptide levels were reduced after exposure of mice to paroxetine (N=5), NAC (N=7), and erythromycin (N=7) relative to matched placebo counterparts. These results demonstrated proof-of concept for a strategy to further screen the APP 5UTR target to identify novel drugs that exhibit anti-amyloid efficacy in vivo. These data also demonstrated a statistically significant antiamyloid trend for paroxetine, NAC and erythromycin. The potential for conducting further studies with these compounds using larger cohorts of TgCRND8 mice is discussed.
Export Options
About this article
Cite this article as:
Tucker Stephanie, Ahl Michelle, Bush Ashley, Westaway David, Huang Xudong and Rogers T. Jack, Pilot Study of the Reducing Effect on Amyloidosis In Vivo by Three FDA Pre-Approved Drugs Via the Alzheimers APP 5Untranslated Region, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585855
DOI https://dx.doi.org/10.2174/1567205053585855 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Parthenolide Blocks Cocaines Effect on Spontaneous Firing Activity of Dopaminergic Neurons in the Ventral Tegmental Area
Current Neuropharmacology Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Current Drug Targets Pathophysiology of Tension-Type Headache: Potential Drug Targets
CNS & Neurological Disorders - Drug Targets Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments
Recent Patents on CNS Drug Discovery (Discontinued) Why are Excipients Important to Neonates?
Current Pharmaceutical Design Safety and Tolerability of Agomelatine: Focus on Hepatotoxicity
Current Drug Metabolism Neural Correlates of Default Mode Network Connectivity in Children with Attention Deficit and Hyperactivity Disorder
Current Medical Imaging Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Clinical and Serological Biomarkers of Treatment’s Response in Multiple Sclerosis Patients Treated Continuously with Interferonβ-1b for More than a Decade
CNS & Neurological Disorders - Drug Targets Tobacco Smoke Exposure, Nicotine, and the Embryologic Origins of Asthma
Current Respiratory Medicine Reviews Botulinum Toxin: A Successful Therapeutic Protein
Current Medicinal Chemistry Meet Our Co-Editor
Current Enzyme Inhibition Near-Infrared Spectroscopy (NIRS): A Non-Invasive In Vivo Methodology for Analysis of Brain Vascular and Metabolic Activities in Real Time in Rodents
Current Vascular Pharmacology Differential Expression of Ribosomal Genes in Brain and Blood of Alzheimer’s Disease Patients
Current Alzheimer Research Is the Clinical Use of Cannabis by Oncology Patients Advisable?
Current Medicinal Chemistry PET Radiotracers for Molecular Imaging of Serotonin 5-HT<sub>1A</sub> Receptors
Current Medicinal Chemistry The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story
Current Neuropharmacology Drug Targets in Stress-Related Disorders
Current Medicinal Chemistry Numeric, Agent-based or System Dynamics Model? Which Modeling Approach is the Best for Vast Population Simulation?
Current Alzheimer Research Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: A Combined Experimental and Computational Approach
CNS & Neurological Disorders - Drug Targets